AstraZeneca (AZN)
(Delayed Data from NSDQ)
$67.75 USD
-0.51 (-0.75%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $67.72 -0.03 (-0.04%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum D VGM
Astrazeneca (AZN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$80.81 | $91.70 | $70.00 | 19.28% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Astrazeneca comes to $80.81. The forecasts range from a low of $70.00 to a high of $91.70. The average price target represents an increase of 19.28% from the last closing price of $67.75.
Analyst Price Targets (7 )
Broker Rating
Astrazeneca currently has an average brokerage recommendation (ABR) of 1.54 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 1.54 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, nine are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 75% and 8.33% of all recommendations. A month ago, Strong Buy made up 75%, while Buy represented 8.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 9 | 9 | 8 | 8 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 0 | 0 |
ABR | 1.54 | 1.54 | 1.54 | 1.41 | 1.41 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/20/2024 | Berenberg Bank | Luisa Hector | Not Available | Strong Buy |
2/12/2024 | BMO Capital Markets | Etzer Darout | Strong Buy | Strong Buy |
1/11/2024 | SVB Securities | Andrew Berens | Strong Buy | Strong Buy |
5/26/2023 | Argus Research Corp. | Jasper Hellweg | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.54 |
ABR (Last week) | 1.54 |
# of Recs in ABR | 12 |
Average Target Price | $80.81 |
LT Growth Rate | 13.60% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 212 of 252 |
Current Quarter EPS Est: | 0.96 |